Wednesday, July 8, 2026

Patent intelligence · US

US 9345775

Compositions for targeted delivery of siRNA

granted A61KA61K31/713A61K47/32A61K47/549
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 10
Applicant portfolio 126
Patent details — US 9345775
Jurisdiction
US
Status
granted
Grant date
May 24, 2016
Expiration
May 19, 2036
Claims
27
CPC classes
A61K, A61K31/713, A61K47/32, A61K47/549
View on Google Patents ↗

Quick answer

US 9345775 (Compositions for targeted delivery of siRNA) is held by Arrowhead Madison, Inc.. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K31/713, A61K47/32, A61K47/549, A61K47/60, A61K47/65

More from Arrowhead Madison, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Expires Jul 31, 2045

    granted
  2. US 12365897

    RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Expires Jul 17, 2045

    granted
  3. US 12365899

    RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

    Arrowhead Pharmaceuticals, Inc. · Expires Jul 17, 2045

    granted
  4. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Expires Feb 6, 2045

    granted
  5. US 12188017

    Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

    Arrowhead Pharmaceuticals, Inc. · Expires Jan 2, 2045

    granted
  6. US 12173086

    Alpha-v beta-6 integrin ligands and uses thereof

    Arrowhead Pharmaceuticals, Inc. · Expires Dec 19, 2044

    granted
  7. US 12116573

    Targeting ligands for therapeutic compounds

    Arrowhead Pharmaceuticals, Inc. · Expires Oct 10, 2044

    granted
  8. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Expires Oct 3, 2044

    granted

Frequently asked questions

What is US patent 9345775?

US 9345775 (Compositions for targeted delivery of siRNA) is held by Arrowhead Madison, Inc.. Status: granted. Granted May 24, 2016. Expires May 19, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9345775?

Arrowhead Madison, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 126 pharmaceutical patents for this assignee.

When does US 9345775 expire?

Our index shows an expiration date of May 19, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.